Xenon Pharmaceuticals Inc X-TOLE Results Update AES 2021 Call Transcript
Good day, and thank you for standing by. Welcome to today's conference call, Xenon Pharmaceuticals provides corporate update. (Operator Instructions) Please be advised today's conference may be recorded. (Operator Instructions)
I'd now like to hand the conference over to Sherry Aulin, Chief Financial Officer of Xenon Pharmaceuticals. Please go ahead.
Good morning. Thank you for joining us on our call and webcast to discuss our XEN1101 program including Phase IIb X-TOLE clinical data that will be presented in a poster session and an Xenon-sponsored scientific symposium at the 2021 Annual Meeting of the American Epilepsy Society or AES.
Joining me today are Ian Mortimer, Xenon's President and Chief Executive Officer; Dr. Chris Kenney, Xenon's Chief Medical Officer; and Dr. Chris Von Seggern, Xenon's Chief Commercial Officer.
Ian will provide some opening remarks, Chris Kenney will provide a summary of the top line X-TOLE data, which was previously announced on October 4, as well as the
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |